Literature DB >> 6190641

Synthesis and secretion of insulin-like growth factor and its binding protein by the perfused rat liver: dependence on growth hormone status.

J C Schwander, C Hauri, J Zapf, E R Froesch.   

Abstract

Isolated livers of normal and hypophysectomized (hypox) rats with or without GH replacement therapy were perfused in an erythrocyte-free recirculating perfusion system for 4 h in the presence of [35S]cysteine. Albumin secretion and synthesis increased in a parallel and linear fashion over 4 h. The albumin secretion rates were 0.53 and 0.21 mg/g liver h-1 in normal and hypox animals, respectively. Insulin-like growth factor (IGF) secretion, measured as insulin equivalents in the fat cell assay as well as in a competitive protein binding assay, and IGF synthesis, as determined from [35S]cysteine incorporation into immunoprecipitable IGF, likewise increased linearly and in parallel throughout the perfusion time. The IGF secretion rate was 50 microU/g liver h-1. The secreted IGF had a molecular weight of approximately 7700 daltons. Secretion and synthesis of IGF were reduced to 11% in hypox rats and were largely restored by human GH replacement therapy (to 86% of normal). A single specific binding protein with an approximate molecular weight of 35,000 was detected in the perfusate. The binding protein was measured by covalent cross-linkage to [125I]IGF I by dimethylsuberimidate. The secretion of this binding protein was 62% of normal in hypox animals and 79% in GH-treated hypox rats. The data suggest that IGF is continuously synthesized and released by the liver. Assuming a half-life for IGF of 3 h in the normal rat, a plasma volume of 8 ml, and a liver weight of 8.5 g, the rate of IGF production by the perfused normal rat liver (50 microU/g liver h-1) would be sufficient to maintain serum IGF at the concentration determined in normal rat serum (approximately 130 microU/ml). This suggests that the liver is the major site of IGF production in the rat.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6190641     DOI: 10.1210/endo-113-1-297

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  71 in total

1.  Serum insulin-like growth factor-I is a marker for assessing the severity of vertebral fractures in postmenopausal women with type 2 diabetes mellitus.

Authors:  I Kanazawa; T Yamaguchi; T Sugimoto
Journal:  Osteoporos Int       Date:  2010-06-08       Impact factor: 4.507

Review 2.  Thyroid hormones and growth hormone secretion.

Authors:  R Valcavi; M Zini; I Portioli
Journal:  J Endocrinol Invest       Date:  1992-04       Impact factor: 4.256

3.  Serum levels of insulin-like growth factor (IGF); IGF-binding proteins-3, -4, and -5; and their relationships to bone mineral density and the risk of vertebral fractures in postmenopausal women.

Authors:  T Yamaguchi; M Kanatani; M Yamauchi; H Kaji; T Sugishita; D J Baylink; S Mohan; K Chihara; T Sugimoto
Journal:  Calcif Tissue Int       Date:  2006-01-06       Impact factor: 4.333

Review 4.  Excitation-transcription coupling in skeletal muscle: the molecular pathways of exercise.

Authors:  Kristian Gundersen
Journal:  Biol Rev Camb Philos Soc       Date:  2010-10-06

Review 5.  Somatomedin-1 (insulin-like growth factor-I) in clinical use. Facts and potential.

Authors:  Z Laron
Journal:  Drugs       Date:  1993-01       Impact factor: 9.546

Review 6.  Somatomedins: chemical and functional characteristics of the different molecular forms.

Authors:  A Barreca; F Minuto
Journal:  J Endocrinol Invest       Date:  1989-04       Impact factor: 4.256

Review 7.  The interrelationship between bone and fat: from cellular see-saw to endocrine reciprocity.

Authors:  H Sadie-Van Gijsen; N J Crowther; F S Hough; W F Ferris
Journal:  Cell Mol Life Sci       Date:  2012-11-21       Impact factor: 9.261

8.  Serum prolidase and IGF-1 as non-invasive markers of hepatic fibrosis during four different periods after bile-duct ligation in rats.

Authors:  Orhan Tarçin; Nursal Gedik; Berna Karakoyun; Veysel Tahan; Gagan Sood; Ciğdem Celikel; Nurdan Tözün
Journal:  Dig Dis Sci       Date:  2007-11-13       Impact factor: 3.199

9.  Insulin Growth Factor-I in Protein-Energy Malnutrition during Rehabilitation in Two Nutritional Rehabilitation Centres in Burkina Faso.

Authors:  S Kouanda; B Doulougou; V De Coninck; L Habimana; B Sondo; R Tonglet; J M Ketelslegers; A Robert
Journal:  J Trop Med       Date:  2009-03-17

Review 10.  Acromegaly update--etiology, diagnosis and management.

Authors:  S Melmed; J A Fagin
Journal:  West J Med       Date:  1987-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.